Iterum Therapeutics Files S-1 Registration

TL;DR

Iterum Therapeutics just filed an S-1, looks like they're raising capital.

AI Summary

Iterum Therapeutics plc filed an S-1 form on June 7, 2024, to register securities. The company, incorporated in Ireland with its principal executive offices in Dublin, is involved in the pharmaceutical preparations industry. Corey N. Fishman serves as the President and Chief Executive Officer.

Why It Matters

This S-1 filing indicates Iterum Therapeutics is preparing to offer new securities to the public, which could impact its capital structure and future operations.

Risk Assessment

Risk Level: medium — S-1 filings are typically associated with new public offerings or significant corporate actions, which inherently carry market and execution risks.

Key Numbers

• 2834 — SIC Code (Identifies the company's industry as Pharmaceutical Preparations.)
• 1231 — Fiscal Year End (Indicates the end of the company's financial reporting year.)

Key Players & Entities

• Iterum Therapeutics plc (company) — Registrant
• Corey N. Fishman (person) — President and Chief Executive Officer
• Ireland (company) — Jurisdiction of incorporation
• Dublin (company) — Location of principal executive offices
• 333-280045 (dollar_amount) — SEC File Number

FAQ

Key Financial Figures

• $0.01 — (i) our ordinary shares, nominal value $0.01 per share (ordinary shares), and (ii) w
• $1.41 — ported on the Nasdaq Capital Market was $1.41 per share. There is no established publ
• $100,000 — e expenses of the dealer-manager, up to $100,000. See Plan of Distribution on page 68 of
• $250 million — non-affiliate public float in excess of $250 million and annual revenues in excess of $100 m
• $100 m — illion and annual revenues in excess of $100 million, or a non-affiliate public float
• $700 m — non-affiliate public float in excess of $700 million, each as determined on an annual

Filing Documents

• d821831ds1.htm (S-1) — 606KB
• d821831dex231.htm (EX-23.1) — 3KB
• d821831dexfilingfees.htm (EX-FILING FEES) — 48KB
• g821831g21h43.jpg (GRAPHIC) — 3KB
• g821831g34m59.jpg (GRAPHIC) — 34KB
• 0001193125-24-157345.txt ( ) — 707KB

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS 24

USE OF PROCEEDS

USE OF PROCEEDS 26

DILUTION

DILUTION 27 DIVIDEND POLICY 28 THE RIGHTS OFFERING 29 DESCRIPTION OF UNITS 38 DESCRIPTION OF WARRANTS 39 DESCRIPTION OF SHARE CAPITAL 41 MATERIAL TAX CONSIDERATIONS 57 PLAN OF DISTRIBUTION 68 LEGAL MATTERS 71 EXPERTS 71 WHERE YOU CAN FIND MORE INFORMATION 72 INCORPORATION BY REFERENCE 73 i Table of Contents ABOUT THIS PROSPECTUS This prospectus is part of a registration statement that we have filed with the Securities and Exchange Commission (the SEC). The exhibits to the registration statement contain the full text of certain contracts and other important documents we have summarized in this prospectus. Since these summaries may not contain all the information that you may find important in deciding whether to purchase our securities, you should review the full text of these documents. The registration statement and the exhibits can be obtained from the SEC as indicated under the sections entitled Incorporation by Reference and Where You Can Find More Information. You should rely only on the information contained in or incorporated by reference in this prospectus, any accompanying prospectus supplement or in any related free writing prospectus filed by us with the SEC. We have not authorized anyone to provide you with different information. This prospectus and any accompanying prospectus supplement do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the securities described in this prospectus or such accompanying prospectus supplement or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is unlawful, including under the sanctions laws and regulations of the European Union or the United States of America. You should assume that the information appearing in this prospectus, any prospectus supplement, the documents incorporated by reference and any related free writing prospectus is accura

View Full Filing

View this S-1 filing on SEC EDGAR